Literature DB >> 2787680

A possible autocrine role for interleukin-6 in two lymphoma cell lines.

C Yee1, A Biondi, X H Wang, N N Iscove, J de Sousa, L A Aarden, G G Wong, S C Clark, H A Messner, M D Minden.   

Abstract

Interleukin-6 (IL-6) is a growth factor with diverse biologic activity. Originally described as a T-cell product that enhances immunoglobulin (Ig) secretion in antigen-stimulated B cells, it also affects the growth of T cells, plasmacytomas, hybridomas, and hematopoietic stem cells. We report the expression and secretion of IL-6 by two lymphoma cell lines, OCI-LY3 and OCI-LY12. Addition of recombinant IL-6 stimulated their growth, whereas addition of polyclonal anti-recombinant IL-6 (anti-rIL-6) had a marked inhibitory effect on proliferation. These results suggest an autocrine role for IL-6 in the growth of these lymphoma cells in culture.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2787680

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  23 in total

1.  Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.

Authors:  D M Nachbaur; M Herold; A Maneschg; H Huber
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

2.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Polymorphisms in immune function genes and non-Hodgkin lymphoma survival.

Authors:  Briseis Aschebrook-Kilfoy; Tongzhang Zheng; Francine Foss; Shuangge Ma; Xuesong Han; Qing Lan; Theodore Holford; Yingtai Chen; Brian Leaderer; Nathaniel Rothman; Yawei Zhang
Journal:  J Cancer Surviv       Date:  2011-11-24       Impact factor: 4.442

4.  Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma.

Authors:  M el-Far; M Fouda; R Yahya; H el-Baz
Journal:  J Physiol Biochem       Date:  2004-12       Impact factor: 4.158

5.  Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma.

Authors:  Toni Valković; Antica Duletić-Načinović; Sanja Stifter; Milena Hasan; Ita Hadžisejdić; David Zombori; Blaženka Grahovac; Nives Jonjić
Journal:  Clin Exp Med       Date:  2010-03-16       Impact factor: 3.984

6.  Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).

Authors:  Takashi Sasayama; Satoshi Nakamizo; Masamitsu Nishihara; Atsufumi Kawamura; Hirotomo Tanaka; Katsu Mizukawa; Shigeru Miyake; Masaaki Taniguchi; Kohkichi Hosoda; Eiji Kohmura
Journal:  Neuro Oncol       Date:  2011-12-12       Impact factor: 12.300

7.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.

Authors:  S J Brandt; D M Bodine; C E Dunbar; A W Nienhuis
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

8.  Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.

Authors:  Lloyd T Lam; George Wright; R Eric Davis; Georg Lenz; Pedro Farinha; Lenny Dang; John W Chan; Andreas Rosenwald; Randy D Gascoyne; Louis M Staudt
Journal:  Blood       Date:  2007-12-26       Impact factor: 22.113

9.  Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of non-Hodgkin lymphoma.

Authors:  Lynn F Sniderhan; Tatiana M Garcia-Bates; Michael Burgart; Steven H Bernstein; Richard P Phipps; Sanjay B Maggirwar
Journal:  Exp Hematol       Date:  2009-08-28       Impact factor: 3.084

10.  Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro.

Authors:  B Barut; D Chauhan; H Uchiyama; K C Anderson
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.